Here we provide an update on high risk Wilms tumors as a part of the @COGorg and @WorldSIOP pediatric renal tumor collaborative #HARMONICA initiative - https://t.co/dlbNBWdgzR
Robust translational partnerships are essential to rapidly advance novel therapies for #childhoodcancer; herein @HeathcliffDora1@anton_gh find ATRi as a novel approach to treat #ARMS which directly informed the actively recruiting @COGorg study PEPN2112 https://t.co/rgEGrlGAb8
🔬TODAY "How Osteosarcoma Evolves from Diagnosis to Relapse" - @MDKinnz of @MSKCancerCenter is joining us on OsteoBites to talk about this evolution.
👉You can join us LIVE today, Thursday at 3pm EDT:
https://t.co/iacT9RnK34
✨This episode is sponsored by @osinstitute (OSI)
"An intercontinental divide for the upfront treatment of Ewing sarcoma has persisted... The EE2012 results harmonise treatment approaches."
@EmilySlotkin & @WTapMD provide a linked Comment: https://t.co/WtaumEicf3
📢The 10th Paediatric Strategy Forum for DNA Damage Repair Pathway Inhibitors has now begun at @EMA_News!
➡️Stay tuned for the summary and manuscript addressing the challenges and documenting the conclusions of the meeting.
#ChildhoodCancer#DrugDevelopment#ACCELERATEcure
Very happy to share this new publication from our lab, led by @HeathcliffDora1 , where we describe that preclinical models of alveolar rhabdomysarcoma are exceptionally sensitive to pharmacological ATR inhibition 🔥🔥👇🏻👇🏻 @NatureComms #1
https://t.co/9gC5YRaSVp
Had a blast this morning sharing a snapshot of my work studying clonal evolution in osteosarcoma! Work made possible by the support of many generous foundations including @ConquerCancerFd@hopeonwheels@quadwfoundation@RallyFoundation.
Hoping to share the full story soon!#ASCO22
Desmoplastic Small Round Cell Tumor is defined by a simple and balanced translocation and characterized by a paucity of recurrent mutations. FGFR4 overexpression may represent a therapeutic vulnerability. https://t.co/9N3FKXSCt7 #DSRCT
Join us for the VIRTUAL Very Rare Cancer Consortium Disease Spotlight & Research Roundtable on #DSCRT, 3/18, 4pm – 6pm. Speakers from @sloan_kettering (including @EmilySlotkin, @MLadanyi, @oleg8r, & @906Madelyn) plus @columbia & @MDAndersonNews. Details: https://t.co/kFSCfNzdS6
It would mean a great deal to me if everyone I know, & everyone you know would RT this post about our genomics cancer projects. Anyone dx'd with a brain tumor or osteosarcoma in the US & Canada can join here: https://t.co/cPi4T8dnkX & https://t.co/Vww0mc4IzE #BTSM#Sarcoma TY!
congratulations to @MLadanyi@lee_spraggon and all others on this paper! clinical trial based on these data evaluating TPX-005 with irinotecan/temozolomide in relapsed/refractory DSRCT will be open in ~2 months @sloan_kettering led by the amazing Dr. Tara O’Donohue #DSRCT
@bvantine1@MLadanyi the clinical trial is undergoing approvals and will be open @sloan_kettering in ~2 months led by dynamo Dr. Tara O’Donohue; will be TPX-005 + irinotecan/temozolomide with a specific cohort for relapsed/refractory #DSRCT patients based on these data...eager to get started!
@VivekSubbiah@MLadanyi the clinical trial is undergoing approvals and will be open @sloan_kettering in ~2 months led by dynamo Dr. Tara O’Donohue; will be TPX-005 + irinotecan/temozolomide with a specific cohort for relapsed/refractory #DSRCT patients based on these data...eager to get started!